Format

Send to

Choose Destination
Drug Discov Today. 2014 Jul;19(7):869-81. doi: 10.1016/j.drudis.2013.11.004. Epub 2013 Nov 15.

Antibody-drug conjugates: current status and future directions.

Author information

1
Bristol-Myers Squibb Research & Development, Princeton, NJ 08543, USA.
2
Bristol-Myers Squibb Research & Development, Redwood City, CA 94063, USA.
3
Bristol-Myers Squibb Research & Development, Princeton, NJ 08543, USA. Electronic address: robert.borzilleri@bms.com.

Abstract

Antibody-drug conjugates (ADCs) aim to take advantage of the specificity of monoclonal antibodies (mAbs) to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells. Despite the simple concept, various parameters must be considered when designing optimal ADCs, such as selection of the appropriate antigen target and conjugation method. Each component of the ADC (the antibody, linker and drug) must also be optimized to fully realize the goal of a targeted therapy with improved efficacy and tolerability. Advancements over the past several decades have led to a new generation of ADCs comprising non-immunogenic mAbs, linkers with balanced stability and highly potent cytotoxic agents. Although challenges remain, recent clinical success has generated intense interest in this therapeutic class.

PMID:
24239727
DOI:
10.1016/j.drudis.2013.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center